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Summary: While performing a prospective study on sCD44 variant isoforms as tumour markers in certain malig-
nancies, we detected relevant differences in the control group between non-smokers and smokers. For a detailed
evaluation of these findings, serum levels of sCD44 variant proteins, including sequences encoded by exon v5 and
exon v6, respectively, were adjusted to sex, age and smoking habit.
We were able to demonstrate a significant elevation of serum levels of sCD44v5 and sCD44v6 in normal individuals
due to cigarette smoking (non-smokers to smokers: sCD44v5: 33 ± 11 g/l to 62 ± 30 g/l; sCD44v6:
142 ± 34 g/l to 232 ± 86 g/l). Stepwise multiple linear regression analysis of the concentrations of sCD44v5
and sCD44v6 on the possible influence factors sex, age and smoking habit revealed cigarette smoking as the only
factor influencing these isoforms (both p «C 0.001). Further investigations have to elucidate a possible clinical
importance of these findings in smokers. However, in patients with suspected or proven malignancy the diagnostic
specifity of sCD44v5 and sCD44v6 is diminished due to this observation.
Introduction
CD44 is a widely-expressed cell surface glycoprotein
that mediates a variety of adhesive processes in cell-
cell and cell-matrix interactions (1—5). The pleiotropic
molecular interactions are mediated by different iso-
forms generated by alternative RNA splicing of at least
10 variably-expressed exons, mainly encoding extracel-
lular regions (6, 7).
The role of CD44 in metastatic disease has been eluci-
dated by the detection of splice variants on metastatic
cells. Based on data obtained with a spontaneous rat
metastasis assay, CD44 splice variants (sharing an epi-
tope within the sequence of exon v6) have been iden-
tified to be functionally involved in tumour dissemina-
tion (8). Variant isoforms have recently been shown
to be expressed on the surface of a variety of human
tumours (9—14). The causal involvement of CD44
variants in the complex process of metastasis forma-
tion was strengthened by the relation of their expres-
sion with tumour progression in colorectal cancer, and
as a poor prognostic factor for overall survival in
breast cancer and in non-//oi/g&m's-lymphoma, respec-
tively (15-17).
Besides tissue expression, soluble CD44 variant iso-
forms are detectable in human serum. Serum levels of
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sCD44 have been proven to be correlated with tumour
load and metastasis in serum of patients with gastric
or colon cancer (18). Measurement of sCD44 variant
proteins could be useful as a tumour marker in pa-
tients with certain solid cancers and haematological
malignancies.
We started a prospective study on sCD44v5 and
sCD44v6 to evaluate the clinical relevance of these new
markers in the diagnosis and follow-up of patients with
certain malignancies. While defining a large control
group of normal individuals, we realized elevated serum
levels for both markers in healthy serum donors who
demonstrated extreme smoking habits. This led us to de-
fine the influence of nicotine abuse on serum concentra-
tions of soluble CD44 variant isoforms in normal in-
dividuals.
Materials and Methods
Serum samples
Blood was drawn by venipuncture from 147 voluntary, healthy
human donors after informed consent was given and centrifuged
immediately. The serum samples were kept at —20 °C prior
to assay.
Enzyme-linked immunosorbent assay for sCD44v5 and
sCD44v6
A commercially available sandwich type ELI S A, developed by
Bender MedSystems Vienna, Vienna, Austria, was used for the
quantitative measurement of sCD44v5 and sCD44v6 in human se-
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rum. A monoclonal antibody specific for an epitope of the CD44
standard molecule served as the capturing antibody adsorbed to
microplates. An antibody specific for the splice variant tested
(VFF8 for an epitope encoded by exon v5, VFF18 for an epitope
encoded by exon v6) coupled to horseradish peroxidase was used
for signal-generating by the peroxidase/tetramethyl-benzidine sys-
tem.
The ELISA tests were performed according to the manufacturers
instructions: Briefly, samples were prediluted with sample diluent
(buffered protein matrix containing 0.1 g/1 thimerosal as preserva-
tive) 1 + 5 for the sCD44v5 assay and 1 + 19 for the sCD44v6
assay. Microwell strips were washed twice with 10 ml/1 Tween-
20 in phosphate-buffered saline. After reconstitution of lyophilized
CD44 variant standards (20 μg/l), 100 μΐ of sample diluent were
added in duplicate to the appropriate standard wells. The standard
protein for both assays in eukariotically (CHO cell line: ovary,
Chinese hamster) expressed recombinant protein containing the
variant sequences (12, 19). Standard dilutions were prepared in
duplicate by pipetting 100 μΐ of the corresponding CD44 standard
into the first standard wells; serial dilutions ranging from 10 to
0.32 μg/l were created by transferring 100 μΐ from well to well.
From the last wells 100 μϊ were discarded. Sample diluent (100 μΐ)
was added to the blank wells. After adding 80 μΐ of sample diluent
to the sample wells, 20 μΐ of prediluted samples were pipetted in
duplicate to the designated wells (giving a final dilution of 1 +29
for sCD44v5 and 1+99 for sCD44v6). The corresponding horse-
radish peroxidase conjugate (50 μΐ) was added to all wells. Incuba-
tion was performed at room temperature for 3 hours on a rotator
platform (100 min"1) followed by three washing steps. Colour de-
velopment was performed with 100 μΐ substrate solution (3,3',5,5'-
tetramethyl-benzidine, Kirkegaard and Perry Laboratories, Inc,
Gaithersburg, USA, and 0.2 g/1 buffered hydrogen peroxide) for 15
minutes and the peroxidase reaction was then stopped by adding
100 μΐ of 2 mol/1 H2SO4. The microwell reader was blanked and
colour intensity was measured at 450 nm (ELISA-reader anthos ht-
II, anthos labtec instruments, Salzburg, Austria).
An evaluation of the reproducibility of sCD44v5 and sCD44v6 val-
ues in our laboratory for two sera gave the following coefficients
of variation: within-assay (n = 10): 4.6% (mean concentration: 56
μg/l) and 3.2% (mean concentration: 127 μg/l) for sCD44v5 deter-
minations, 1.3% (mean concentration: 230 μg/l) and 2.4% (mean
concentration: 392 μg/l) for sCD44v6 determinations, between-as-
say (n = 12): 5.9% (mean concentration: 56 μg/l) and 6.9% (mean
concentration: 127 μg/l) for sCD44v5 determinations, 5.2% (mean
concentration: 230 μg/l) and 8.8% (mean concentration: 392 μg/l)
for sCD44v6 determinations. These results are in accordance with
the data published by the manufacturer. Further performance char-
acteristics regarding sensitivity, specifity, recovery studies and
comparison of serum and plasma are given in the package inserts
included in the test kits (20, 21).
Statistics
Results are described by means, medians and standard deviations.
The relations between sex, age and smoking habit have been inves-
tigated by t-test, by analysis of variance (ANOVA) and by Chi-
square-test. The dependence of sCD44v5 and sCD44v6 on age, sex
and cigarette smoking has been analyzed by stepwise multiple lin-
ear regression analysis (Superior Performing Statistical Software
SPSS 6.0 inc., Chicago, Illinois 1993).
Results
The concentrations of sCD44v5 and sCD44v6 were
measured in serum samples of unselected healthy do-
nors. First results showed an excessive positive skew-
ness for both markers implicating a bimodal distribution
that could not be explained by sex or age (n = 125, data
not shown). Subsequently, the distribution of sCD44v5
and sCD44v6 in 147 additional voluntary human serum
donors was analyzed with respect to the smoking habits.
Characteristics of serum donors are given in table 1. The
samples of all smokers (n = 51) were further assigned
to two groups according to the number of cigarettes
smoked per day: group I (n = 44): 5—20 cigarettes per
day; group II (n = 7): > 20 cigarettes regularly per day
in agreement with the persons assertions. With respect
to the variables age, sex and smoking habit, the samples
were distributed equally (two-sided comparison of the
average age between sex, t-test, p = 0.98; comparison
of average age between non-smokers and smokers,
analysis of variance, p = 0.63; Chi-square-test for sex
versus smoking habit, p = 0.30). The distributions of
sCD44v5 and sCD44v6 concentrations in serum samples
are shown for non-smokers and all smokers (including
group I and group II) in figure 1 and figure 2, respec-
tively. Means, medians and standard deviations are
given in table 2, including separate estimates for the two
subgroups of smokers. For both sCD44 isoforms the data
show a marked dependence on smoking habits. Stepwise
multiple linear regression analysis of the concentrations
of sCD44v5 and sCD44v6 on the possible influence
factors sex, age and smoking habit revealed cigarette
smoking and its intensity as the only factors influencing
these isoforms (both p <C 0.001). No dependence on sex
or age was found (sCD44v5: sex, p = 0.92, age,
ρ = 0.64; sCD44v6: sex, ρ = 0.90, age, ρ = 0.79).
Discussion
We were able to demonstrate a significant elevation
of serum concentrations of sCD44v5 and sCD44v6 in
normal individuals who smoke cigarettes. As much as
37% of the biological variability of sCD44v5 and 36%
of the biological variability of sCD44v6 serum levels
are explained by a linear trend on cigarette smoking
alone.
The cellular origin of sCD44 variant isoforms in human
serum is not yet known. Theoretically, the soluble iso-
forms might result from proteolytic release of the extra-
cellular domain or by alternative splicing that leads to
mRNA encoding only the extracellular domain. Because
mRNA splice variants corresponding to the extracellular
domain alone have not yet been reported, CD44 proteins
Tab. 1 Characteristics of healthy serum donors
Total
Male
Female
Sample
size
147
80
67
Age3
a)
38.1 (± 10)
38.2 (± 10)
38.1 (± 10)
Non-
smok-
ers
96
48
48
Smokers
Ib
44
27
17
IP
7
5
2
a
 Means ± SD are given
b
 group I: 5—20 cigarettes per day,
c
 group II: > 20 cigarettes regularly per day.
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Fig. 1 Histogram of relative frequencies of sCD44v5 concentra-
tions in serum samples from 147 normal human individuals with
regard to smoking habits, a. Non-smokers (n = 96), b. Smokers
(n = 51), see also table 2.
seem to be released into the blood by shedding from
vital cells or by proteolytic release of decaying cells.
Whether or not sCD44 molecules retain biological func-
tion comparable to other soluble forms of cellular adhe-
sion molecules remains unkown (22).
Strong expression of CD44v5 and CD44v6 is detectable
in bronchial epithelium and pneumocytes type II in nor-
mal human lung tissue (10, 19). Expression of CD44
splice variants might be upregulated in these cells in
chronic nicotine abusers. However, these epithelia are
endoluminal and shedding from these cells into the cir-
culation is thought to be inhibited by the intact basal
membrane. Therefore, elevated serum levels of sCD44
variant proteins in individuals who smoke cigarettes are
unlikely to be caused by shedding of CD44 isoforms
from these cells.
Another explanation for elevated serum concentrations
of sCD44 variant isoforms in smokers could be due to
Soluble CD44v6 [pg/l]
Fig. 2 Histogram of relative frequencies of sCD44v6 concentra-
tions in serum samples from 147 normal human individuals with
regard to smoking habits, a. Non-smokers (n = 96), b. Smokers
(n = 51), see also table 2.
the chronic bronchial inflammation. CD44 molecules
are involved in multiple proinflammatory steps includ-
ing T cell activation, T cell adhesion to monocytes, cy-
tokine release and regulation of the function of other
adhesion molecules (1—5, 23). Upregulation of CD44
splice variants on myelomonocytic cells and human en-
dothelial cells has been reported in response to the in-
flammatory cytokines tumour necrosis factor-α (TNFa)
and interferon-γ (IFNy) (4, 23). The effect of these cy-
tokines on CD44 expression was also examined on epi-
thelial cells (upregulation of CD44v6 by IFNy) and fi-
broblasts (upregulation of a molecule, structurally re-
lated to CD44, by TNFa). In immunohistochemical
analysis pulmonary macrophages were stained by a mo-
noclonal antibody targeting sequences of exon v6 (23).
Thus elevated serum levels may result from the activa-
tion of proinflammatory pathways in nicotine-distressed
lungs. Smoking considerably elevates the concentration
of sCD44v5 and sCD44v6 in the circulation. Further in-
Tab. 2 ELISA measurements of sCD44v5 and sCD44v6 concentrations in normal human serum
samples, analyzed with regard to smoking habits
Sample size sCD44v5
fog/I)
Non-smokers
All smokers
Group P
Group IIb
96
51
44
7
mean
33
62
59
79
median
30
56
56
55
SD
11
30
27
44
sCD44v6
fog/I)
mean
142
232
227
266
median
140
215
216
215
SD
34
86
82
107
group I: 5-20 cigarettes per day; b group II: > 20 cigarettes regularly per day.
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vestigations have to elucidate a possible biological im-
portance of these findings in smokers. However, in pa-
tients with suspected or proven malignancy the diagnos-
tic specifity of sCD44v5 and sCD44v6 is considerably
diminished due to our observation.
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